Plant alkaloid · Fact sheet
Berberine
Berberine has human studies suggesting glucose and lipid effects, but weight-loss evidence is inconsistent. It is not an approved replacement for diabetes or obesity medicines and can cause gastrointestinal symptoms and drug interactions.
What is Berberine?
Berberine is an alkaloid found in several plants. It is not a peptide or a GLP-1 receptor agonist.
Benefits & claims
Glucose control, weight loss, and lipid changes drive interest. Calling it a natural equivalent of a prescription GLP-1 medicine skips major differences in evidence and mechanism.
What the evidence supports
- A three-month pilot in adults with type 2 diabetes found improved glucose measures.
- This does not establish equal long-term benefit or safety to approved medicines, and weight-loss findings remain inconclusive.
Research areas
- Glucose regulation
- Lipids
- Body weight
Dosage & frequency
Human study contextA small diabetes trial supplies a study regimen, but berberine is not an FDA-approved diabetes or weight-loss medicine.
Pilot type 2 diabetes trial
Newly diagnosed adults with type 2 diabetes
- Amount
- 500 mg per dose
- Frequency
- Three times daily for three months
- Route studied or labeled
- Oral
Small disease-specific study; not FDA-approved diabetes treatment.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Results for berberine hydrochloride are not automatically transferable to dihydroberberine or combination products.
Interactions & precautions
- NCCIH notes medicine interactions, including cyclosporine; effects on drug exposure need product-specific review.
What is still unresolved
- A reproducible weight-management regimen and long-term clinical outcomes remain uncertain.
Side effects & risks
- Nausea, abdominal discomfort, constipation, and diarrhea are reported.
- Human research shows inhibition of drug-metabolizing enzymes, creating interaction concerns.
- Pregnancy, breastfeeding, and infant exposure raise specific bilirubin-related safety concerns.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Early human evidenceA small diabetes pilot and other short studies show metabolic signals. Study quality, formulation differences, and limited long-term outcomes restrict the conclusions.
Studies
Small three-month study; biomarker outcomes and gastrointestinal adverse effects.
Crossover study demonstrating CYP2D6, CYP2C9, and CYP3A4 inhibition.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 3 sourced accounts by reported effect.
Appetite: reported experiences
Fewer cravings followed by significant illness
A poster described slightly reduced cravings and some weight loss while also dieting, then nausea, diarrhea and later episodes of vomiting, fever, shaking and a racing heart.
Reported use in this account
- Product
- Berberine pills; formulation not stated
- Amount
- 500 mg initially; later amounts of 1,000 mg and 1,500 mg were reported
- Frequency
- Daily for the initially stated amount; later frequency not clarified
- Route
- Not specified clearly
- Duration
- About four weeks before the first severe episode
Dieting complicates the reported benefit. No diagnosis or product analysis was independently verified; the severe later illness cannot be confidently assigned to berberine.
Read the personal accountWeight: reported experiences
Weight loss and more energy during lifestyle changes
A commenter described weight loss and more energy over three months while also changing meals and post-meal activity.
Reported use in this account
- Product
- Berberine supplement; formulation not stated
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Three months
Concurrent behavior changes prevent assigning the weight or energy changes to berberine.
Read the original accountFewer cravings followed by significant illness
A poster described slightly reduced cravings and some weight loss while also dieting, then nausea, diarrhea and later episodes of vomiting, fever, shaking and a racing heart.
Reported use in this account
- Product
- Berberine pills; formulation not stated
- Amount
- 500 mg initially; later amounts of 1,000 mg and 1,500 mg were reported
- Frequency
- Daily for the initially stated amount; later frequency not clarified
- Route
- Not specified clearly
- Duration
- About four weeks before the first severe episode
Dieting complicates the reported benefit. No diagnosis or product analysis was independently verified; the severe later illness cannot be confidently assigned to berberine.
Read the personal accountEnergy: reported experiences
Weight loss and more energy during lifestyle changes
A commenter described weight loss and more energy over three months while also changing meals and post-meal activity.
Reported use in this account
- Product
- Berberine supplement; formulation not stated
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Three months
Concurrent behavior changes prevent assigning the weight or energy changes to berberine.
Read the original accountDigestion: reported experiences
Fewer cravings followed by significant illness
A poster described slightly reduced cravings and some weight loss while also dieting, then nausea, diarrhea and later episodes of vomiting, fever, shaking and a racing heart.
Reported use in this account
- Product
- Berberine pills; formulation not stated
- Amount
- 500 mg initially; later amounts of 1,000 mg and 1,500 mg were reported
- Frequency
- Daily for the initially stated amount; later frequency not clarified
- Route
- Not specified clearly
- Duration
- About four weeks before the first severe episode
Dieting complicates the reported benefit. No diagnosis or product analysis was independently verified; the severe later illness cannot be confidently assigned to berberine.
Read the personal accountAcute illness: reported experiences
Fewer cravings followed by significant illness
A poster described slightly reduced cravings and some weight loss while also dieting, then nausea, diarrhea and later episodes of vomiting, fever, shaking and a racing heart.
Reported use in this account
- Product
- Berberine pills; formulation not stated
- Amount
- 500 mg initially; later amounts of 1,000 mg and 1,500 mg were reported
- Frequency
- Daily for the initially stated amount; later frequency not clarified
- Route
- Not specified clearly
- Duration
- About four weeks before the first severe episode
Dieting complicates the reported benefit. No diagnosis or product analysis was independently verified; the severe later illness cannot be confidently assigned to berberine.
Read the personal accountNo clear change: reported experiences
No noticeable result
A separate commenter reported that berberine did not do anything they could notice.
Amount, frequency, route and duration could not be confirmed for this account.
The short comment gives little information about exposure, goals or concurrent treatments.
Read the original accountApproval status
Berberine has no FDA-approved drug indication for the wellness uses discussed here. Supplement availability is not premarket FDA approval of effectiveness or safety.
Supplement research is not FDA drug approval
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Reliable long-term weight-loss effects
- Effects on complications rather than biomarkers alone
- Which results generalize across formulations
Summary
This does not establish equal long-term benefit or safety to approved medicines, and weight-loss findings remain inconclusive.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedBerberine pilot study in type 2 diabetes
Small three-month study; biomarker outcomes and gastrointestinal adverse effects.
- pubmedBerberine and drug-metabolizing enzymes in humans
Crossover study demonstrating CYP2D6, CYP2C9, and CYP3A4 inhibition.
- nihNCCIH: berberine and weight loss
Evidence limitations, interactions, gastrointestinal symptoms, and infant/pregnancy concerns.
- fdaFDA: what approval means for supplements
Dietary supplements are not approved by FDA for safety and effectiveness before marketing.